Literature DB >> 11192373

Mouse models of focal arterial and venous thrombosis.

J Dörffler-Melly1, L A Schwarte, C Ince, M Levi.   

Abstract

Mouse models of arterial and venous thrombosis have gained increasing interest over the last 15 years, due to direct availability of a growing number of genetically modified mice, improved technical feasibility, standardization of new models of local thrombosis, and low maintenance costs. In order to provide an overview of suitable models for the study of arterial and venous thrombosis in mice, we have systematically searched MEDLINE electronic databases for publications reporting on murine thrombo-embolic models from 1966-1999. We found that the variety of murine thromboembolic models through 1995 was rather limited, as most methods used intravenous injections of strong coagulation triggers such as thrombin, thromboplastin and collagen, causing lethal thromboembolism. Between 1996 and the end of 1999, a number of more sophisticated murine models of local acute or chronic thrombosis have been established. They seem to be more suitable for mimicking the natural scenario of thrombosis and, therefore, are preferable models for pathophysiological or drug evaluation studies. In this paper various models are described and their advantages and limitations discussed.

Entities:  

Mesh:

Year:  2000        PMID: 11192373     DOI: 10.1007/s003950070028

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  8 in total

1.  Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.

Authors:  Jose A Diaz; Nicole E Ballard-Lipka; Diana M Farris; Angela E Hawley; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Daniel A Lawrence; Thomas W Wakefield
Journal:  J Vasc Surg       Date:  2011-11-25       Impact factor: 4.268

2.  High-resolution magnetic resonance angiography in the mouse using a nanoparticle blood-pool contrast agent.

Authors:  Gabriel P Howles; Ketan B Ghaghada; Yi Qi; Srinivasan Mukundan; G Allan Johnson
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

3.  Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.

Authors:  A T Obi; J A Diaz; N L Ballard-Lipka; K J Roelofs; D M Farris; D A Lawrence; T W Wakefield; P K Henke
Journal:  J Thromb Haemost       Date:  2014-07-23       Impact factor: 5.824

Review 4.  Atherosclerosis and thrombosis: insights from large animal models.

Authors:  Gemma Vilahur; Teresa Padro; Lina Badimon
Journal:  J Biomed Biotechnol       Date:  2011-01-02

5.  Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.

Authors:  Qianxing Zhou; Florian Bea; Michael Preusch; Hongjie Wang; Berend Isermann; Khurrum Shahzad; Hugo A Katus; Erwin Blessing
Journal:  Mediators Inflamm       Date:  2011-06-07       Impact factor: 4.711

6.  Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes.

Authors:  Dirkje W Sommeijer; René van Oerle; Pieter H Reitsma; Janneke J Timmerman; Joost C M Meijers; Henri M H Spronk; Hugo ten Cate
Journal:  Thromb J       Date:  2005-08-22

7.  Antiplatelet Aggregation and Antithrombosis Efficiency of Peptides in the Snake Venom of Deinagkistrodon acutus: Isolation, Identification, and Evaluation.

Authors:  Bin Ding; Zhenghong Xu; Chaodong Qian; Fusheng Jiang; Xinghong Ding; Yeping Ruan; Zhishan Ding; Yongsheng Fan
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-21       Impact factor: 2.629

Review 8.  Fibrinolysis and Inflammation in Venous Thrombus Resolution.

Authors:  Subhradip Mukhopadhyay; Tierra A Johnson; Nadire Duru; Marguerite S Buzza; Nisha R Pawar; Rajabrata Sarkar; Toni M Antalis
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.